{"title":"LAI antipsychotics show effective results in comparative analysis","authors":"","doi":"10.1002/pu.31263","DOIUrl":null,"url":null,"abstract":"<p>Long-acting injectable (LAI) formulations of paliperidone and aripiprazole were among the most effective antipsychotics for limiting patient relapse in a comparative effectiveness study using health care register data for patients with schizophrenia. The 3-month formulation of LAI paliperidone was associated with the lowest risk of the adverse outcomes.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"3-4"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31263","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Long-acting injectable (LAI) formulations of paliperidone and aripiprazole were among the most effective antipsychotics for limiting patient relapse in a comparative effectiveness study using health care register data for patients with schizophrenia. The 3-month formulation of LAI paliperidone was associated with the lowest risk of the adverse outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
